This analysis demonstrated significant variability in medical policy determinations and evidence cited for clinically relevant pharmacogenetic tests among major US health insurers and laboratory benefit managers.
Emily Reese, PhD, MPH
Advertisement
Articles by Emily Reese, PhD, MPH
Advertisement
Latest Updated Articles
Medical Policy Determinations for Pharmacogenetic Tests Among US Health PlansPublished: February 10th 2025 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
AHA Launches New Initiative to Help Patients With Heart Failure
2
Medicaid Work Rules Could Strain Hospitals: Laxmi Patel
3
CSU More Burdensome in Female Patients, Especially in Midlife
4
Pirtobrutinib Shows Clinically Meaningful PFS Improvement in Frontline CLL
5
